Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of ACINO Goserelin 10.8 mg Implant in Prostate Cancer
2009-016200-23Phase 3Active
- Sponsor
- Acino
- Start
- Oct 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Acino. Primary endpoint: Testosterone suppression below castrate level. Started Oct 2009; status: active.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-016200-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016200-23.